Enrolling Now

Be part of developing furmonertinib, an oral, highly brain-penetrant mutation selective EGFR inhibitor for first-line patients with non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertion mutations

FURVENT Study Design

A Global Phase 3 Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

ClinicalTrials.gov NCT#05607550

Furmonertinib is an investigational drug and is not approved for this indication.

Why the FURVENT trial?

  • Ongoing Phase 1ba study showed clinical activity of furmonertinib in treatment-naive patients and safety data consistent with previous clinical studies
  • FURVENT trial is designed to compare 2 furmonertinib arms versus chemotherapy
  • Patients with brain metastases may be eligible to participate
  • Crossover from the control arm to furmonertinib is permitted following disease progression
  • Furmonertinib granted Breakthrough Therapy Designation by FDA in first-line treatment of NSCLC EGFR exon 20 insertion mutations

a. Han, B, et al. FAVOUR: A phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR Exon 20 insertions. Oral presentation at WCLC, September 2023.

Have a patient referral? Contact [email protected] or 628-277-4836

Key Inclusion Criteria

  • Histologically or cytologically documented, locally advanced or metastatic non-squamous NSCLC not amenable to curative surgery or radiotherapy
  • Documented results of the presence of an Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutation in tumor tissue or blood from local or central testing
  • No prior systemic anticancer therapy regimens received for locally advanced or metastatic NSCLC including prior treatment with any EGFR-targeting agents (e.g., previous EGFR TKIs, monoclonal antibodies, or bispecific antibodies)
  • Patients who have received prior neo-adjuvant and/or adjuvant chemotherapy, immunotherapy, or chemo-radiotherapy (excluding EGFR TKIs) for non-metastatic disease must have experienced a treatment free interval of at least 12 months
  • Patients with a history of treated CNS metastases or new asymptomatic CNS metastases are eligible

FURVENT Locations

For more information about this study and where it is being conducted, please contact:

Phone Number: 628-277-4836

Email Address: [email protected]